Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092503170> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W3092503170 endingPage "14" @default.
- W3092503170 startingPage "8" @default.
- W3092503170 abstract "can induce serious adverse events such as edema and heart failure (HF). Some previous studies showed that the efficacy on glucose control and lipid levels was not related to the difference in doses of PIO in opposite to the incidence of edema which was doses-dependent of PIO. To compare glucose control, lipid control, adverse events, and pharmacokinetic (PK) parameters between low and high doses of PIO in T2D. Medical chart of 139 diabetic patients using PIO at Ramathibodi hospital were reviewed to compare outcomes and adverse effects between low and high doses of PIO. 38 patients who stabilized dose of PIO and agree to participate were recruited to collect 2 blood samples at 2 appropriated times and were analyzed their PIO concentrations, then, PK parameters were determined. The outcomes of glucose control and lipid control were not differences between low and high dose of PIO, but edema and HF events were significantly higher in high dose of PIO (P=0.010 and P=0.014, respectively). For PK parameters of PIO, elimination rate constant (ke) and clearance rate (CL) values of patients who were stabilized on high dose of PIO were significantly higher (P=0.022 and P=0.031, respectively) while elimination half-life (t1/2) was significantly shorter (P=0.007) than those who were stabilized on low dose of PIO. PK monitoring for optimal dose of PIO might possibly provide good controlling of blood glucose and lower adverse events in T2D." @default.
- W3092503170 created "2020-10-15" @default.
- W3092503170 creator A5027315543 @default.
- W3092503170 creator A5088403547 @default.
- W3092503170 date "2012-01-01" @default.
- W3092503170 modified "2023-09-23" @default.
- W3092503170 title "COMPARISONS OF EFFECTIVENESS, SAFETY, AND PHARMACOKINETIC PARAMETERS BETWEEN LOW AND HIGH DOSES OF PIOGLITAZONE IN TYPE 2 DIABETIC PATIENTS" @default.
- W3092503170 cites W1596678070 @default.
- W3092503170 cites W1966243777 @default.
- W3092503170 cites W1975781731 @default.
- W3092503170 cites W1979624317 @default.
- W3092503170 cites W1982311681 @default.
- W3092503170 cites W1999225509 @default.
- W3092503170 cites W2015279471 @default.
- W3092503170 cites W2017022117 @default.
- W3092503170 cites W2017505271 @default.
- W3092503170 cites W2023447984 @default.
- W3092503170 cites W2066708831 @default.
- W3092503170 cites W2098476671 @default.
- W3092503170 cites W2105719905 @default.
- W3092503170 cites W2111184067 @default.
- W3092503170 cites W2165832533 @default.
- W3092503170 cites W2185435127 @default.
- W3092503170 cites W2409759064 @default.
- W3092503170 cites W40400977 @default.
- W3092503170 hasPublicationYear "2012" @default.
- W3092503170 type Work @default.
- W3092503170 sameAs 3092503170 @default.
- W3092503170 citedByCount "0" @default.
- W3092503170 crossrefType "journal-article" @default.
- W3092503170 hasAuthorship W3092503170A5027315543 @default.
- W3092503170 hasAuthorship W3092503170A5088403547 @default.
- W3092503170 hasConcept C112705442 @default.
- W3092503170 hasConcept C120665830 @default.
- W3092503170 hasConcept C121332964 @default.
- W3092503170 hasConcept C126322002 @default.
- W3092503170 hasConcept C134018914 @default.
- W3092503170 hasConcept C197934379 @default.
- W3092503170 hasConcept C2777180221 @default.
- W3092503170 hasConcept C2778384471 @default.
- W3092503170 hasConcept C555293320 @default.
- W3092503170 hasConcept C61511704 @default.
- W3092503170 hasConcept C71924100 @default.
- W3092503170 hasConcept C98274493 @default.
- W3092503170 hasConceptScore W3092503170C112705442 @default.
- W3092503170 hasConceptScore W3092503170C120665830 @default.
- W3092503170 hasConceptScore W3092503170C121332964 @default.
- W3092503170 hasConceptScore W3092503170C126322002 @default.
- W3092503170 hasConceptScore W3092503170C134018914 @default.
- W3092503170 hasConceptScore W3092503170C197934379 @default.
- W3092503170 hasConceptScore W3092503170C2777180221 @default.
- W3092503170 hasConceptScore W3092503170C2778384471 @default.
- W3092503170 hasConceptScore W3092503170C555293320 @default.
- W3092503170 hasConceptScore W3092503170C61511704 @default.
- W3092503170 hasConceptScore W3092503170C71924100 @default.
- W3092503170 hasConceptScore W3092503170C98274493 @default.
- W3092503170 hasIssue "1" @default.
- W3092503170 hasLocation W30925031701 @default.
- W3092503170 hasOpenAccess W3092503170 @default.
- W3092503170 hasPrimaryLocation W30925031701 @default.
- W3092503170 hasRelatedWork W1522113235 @default.
- W3092503170 hasRelatedWork W1567093432 @default.
- W3092503170 hasRelatedWork W195141601 @default.
- W3092503170 hasRelatedWork W2055573745 @default.
- W3092503170 hasRelatedWork W2057691777 @default.
- W3092503170 hasRelatedWork W2077521501 @default.
- W3092503170 hasRelatedWork W2090031686 @default.
- W3092503170 hasRelatedWork W2097275353 @default.
- W3092503170 hasRelatedWork W2122285449 @default.
- W3092503170 hasRelatedWork W2123549473 @default.
- W3092503170 hasRelatedWork W2802617131 @default.
- W3092503170 hasRelatedWork W2897213984 @default.
- W3092503170 hasRelatedWork W2948056808 @default.
- W3092503170 hasRelatedWork W3010648955 @default.
- W3092503170 hasRelatedWork W3045697709 @default.
- W3092503170 hasRelatedWork W3083728125 @default.
- W3092503170 hasRelatedWork W3093971607 @default.
- W3092503170 hasRelatedWork W3116670121 @default.
- W3092503170 hasRelatedWork W3126617736 @default.
- W3092503170 hasRelatedWork W3176394421 @default.
- W3092503170 hasVolume "2" @default.
- W3092503170 isParatext "false" @default.
- W3092503170 isRetracted "false" @default.
- W3092503170 magId "3092503170" @default.
- W3092503170 workType "article" @default.